Evidence map›Paper›PMID 42774704›Full record

ArticleNew microbes and new infections2026

A cross sectional seroprevalence study of

Mina Latifian, Malihe Hasannezhad, Ladan Abbasian, Zahra Tahmasebi Ashtiani, Mina Arabian, Fahimeh Bagheri Amiri, Saber Esmaeili

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mina LatifianDepartment of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Malihe HasannezhadIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Department of Infectious Diseases, Imam Khomeini Hospital Complex, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
Ladan AbbasianIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Department of Infectious Diseases, Imam Khomeini Hospital Complex, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
Zahra Tahmasebi AshtianiDepartment of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Mina ArabianDepartment of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Fahimeh Bagheri AmiriDepartment of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Saber EsmaeiliDepartment of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This cross-sectional study included 200 participants, comprising 97 HIV-positive patients, 53 patients with AIDS, and 50 healthy individuals as the control group. IgG antibodies against Results: The overall seroprevalence of Conclusion: The significant prevalence of IgG antibodies against both

Indexed as

AIDSBartonella henselaeBartonella quintanaHIVIFAIran

Identifiers

PMID42774704
PMCPMC13595117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.